Bladder cancer detection and monitoring: Assessment of urine- and blood-based marker tests

Molecular Diagnosis and Therapy

Volumn 17, Issue 2, 2013, Pages 71-84

  Goodison, Steve ^a   Rosser, Charles J ^a   Urquidi, Virginia ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER TUMOR ASSOCIATED ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENT FACTOR H; CYTOKINE; ENDOSTATIN; GELATINASE A; HEAT SHOCK PROTEIN; MATRILYSIN; NUCLEAR MATRIX PROTEIN 22; NUCLEAR MITOTIC APPARATUS PROTEIN 1; UNCLASSIFIED DRUG; UVOMORULIN;

ANEUPLOIDY; BLADDER CANCER; BLADDER TUMOR ASSOCIATED ANTIGEN ASSAYS; CANCER CYTODIAGNOSIS; CANCER SPECIFIC SURVIVAL; CIRCULATING TUMOR CELL; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOCYT TEST; MICROSCOPY; NUCLEAR MATRIX PROTEIN 22 ASSAY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY; UROVYSION BLADDER CANCER KIT;

HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84877354258     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0023-x     Document Type: Review

References (157)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239-49.
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680-4. (Pubitemid 30637601)
4. Trivedi D, Messing EM. Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol. 2009;9:13.
5. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol. 2009;22(Suppl 2):S53-9.
6. Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol. 2009;9:12.
7. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol. 2006;36(3):172-5.
8. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002;41(3):284-9. (Pubitemid 35303426)
9. Washino S, Hirai M, Matsuzaki A, Kobayashi Y. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Urol Int. 2011;87(4):420-8.
10. Gakis G, Todenhofer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol. 2011;21(5):428-33.
11. Schwamborn K, Gaisa NT, Henkel C. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers. Expert Rev Proteomics. 2010;7(6):897-906.
12. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2012;4:S0302-2838.
13. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol. 1990;21(9):886-96. (Pubitemid 20308410)
14. Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006;97(5):997-1001.
15. Gutiérrez Baños JL, del Henar Rebollo Rodrigo M, Antolín Juárez FM, García BM. Usefulness of the BTA STAT test for the diagnosis of bladder cancer. Urology. 2001;57(4):685-9.
16. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47(6):736-48. (Pubitemid 40745338)
17. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem. 1999;45(4):472-7. (Pubitemid 29165956)
18. Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay) - useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med. 2003;41(1):104-10. (Pubitemid 36285393)
19. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology. 1997;50(6):882-7. (Pubitemid 28021105)
20. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161(2):388-94.
21. Oge O, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol. 2002;167(3):1318-9 (discussion 1319-20). (Pubitemid 34132079)
22. Hennenlotter J, Huber S, Todenhofer T, Kuehs U, Schilling D, Aufderklamm S, et al. Point-of-care tests for bladder cancer: the influencing role of hematuria. Adv Urol. 2011;2011:937561.
23. Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ. Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol. 2012;30:869-73.
24. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001;166(1):75-8. (Pubitemid 32565346)
25. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology. 2004;64(4):687-92. (Pubitemid 39446044)
26. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun. 1974;60(4):1410-7.
27. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810-6. (Pubitemid 40250364)
28. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299-305. (Pubitemid 43112958)
29. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 2009;103(10):1368-74.
30. Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study. Can J Urol. 2012;19(4):6345-50.
31. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. 2012;110(5):699-708.
32. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999;162(1):53-7. (Pubitemid 29420879)
33. Yokoyama T, Sekigawa R, Hayashi T, Horita S, Kanamuro T, Nonami Y, et al. The clinical efficacy of Bladder Chek NMP22 in urothelial cancer. Rinsho Byori. 2004;52(3):199-203.
34. Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H. False-positive results of the NMP22 test due to hematuria. J Urol. 2002;167(2 Pt 1):555-8. (Pubitemid 34074526)
35. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ. Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol. 2012;12:23.
36. Greene KL, Berry A, Konety BR. Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol. 2006;8(4):190-7.
37. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol. 2010;32(1):45-52.
38. Hautmann S, Toma M, Lorenzo Gomez MF, Friedrich MG, Jaekel T, Michl U, et al. ImmunoCyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol. 2004;46(4):466-71. (Pubitemid 39200854)
39. Lodde M, Mian C, Comploj E, Palermo S, Longhi E, Marberger M, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology. 2006;67(5):950-4. (Pubitemid 43956447)
40. Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005;174(4 Pt 1):1238-41. (Pubitemid 41318690)
41. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer. 2006;108(1):60-5. (Pubitemid 43291246)
42. Tetu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol. 2005;18(1):83-9. (Pubitemid 40128099)
43. Toma MI, Friedrich MG, Hautmann SH, Jakel KT, Erbersdobler A, Hellstern A, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004;22(2):145-9. (Pubitemid 41406564)
44. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, et al. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol. 2010;118(5):259-68.
45. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164(5):1768-75.
46. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006;176(1):44-7. (Pubitemid 43833178)
47. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005;96(9):1280-5. (Pubitemid 41743924)
48. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167(5):2001-6. (Pubitemid 34309646)
49. Riesz P, Lotz G, Paska C, Szendroi A, Majoros A, Nemeth Z, et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res. 2007;13(3):187-94. (Pubitemid 350221220)
50. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer. 2007;111(6):517-24. (Pubitemid 350304904)
51. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2007;51(5):1275-80 (discussion 1280). (Pubitemid 46436295)
52. Fritsche HM, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W, et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 2010;134(4):597-603.
53. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol. 2009;43(6):461-6.
54. Todenhofer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, et al. Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol. 2012;187(1):68-73.
55. Todenhofer T, Hennenlotter J, Aufderklamm S, Kuhs U, Gakis G, Germann M, et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol. 2012;139(1):49-56.
56. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 2003;92(9):911-4. (Pubitemid 37548264)
57. Bravaccini S, Casadio V, Gunelli R, Bucchi L, Zoli W, Amadori D, et al. Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. Ann Oncol. 2011;22(10):2294-8.
58. Nguyen CT, Stephenson AJ, Kattan MW. Are nomograms needed in the management of bladder cancer? Urol Oncol. 2010;28(1):102-7.
59. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003;170(6 Pt 1):2248-52. (Pubitemid 37413969)
60. Vasala K, Kuvaja P, Turpeenniemi-Hujanen T. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol. 2008;29(5):279-86.
61. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010;116(19):4513-9.
62. Szarvas T, Becker M, vom Dorp F, Gethmann C, Totsch M, Bankfalvi A, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010;101(5):1300-8.
63. Szarvas T, Laszlo V, Vom Dorp F, Reis H, Szendroi A, Romics I, et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. Int J Cancer. 2012;130(12):2922-9.
64. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985-92. (Pubitemid 33136192)
65. Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003;61(5):1053-8. (Pubitemid 36547769)
66. Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011;11:336.
67. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012;188(1):21-6.
68. Fujii Y, Kageyama Y, Kawakami S, Kihara K, Oshima H. Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res. 1999;90(7):753-7. (Pubitemid 29381105)
69. Li SM, Zhang ZT, Chan S, McLenan O, Dixon C, Taneja S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999;162(3 Pt 1):931-5. (Pubitemid 29436920)
70. Lu JJ, Kakehi Y, Takahashi T, Wu XX, Yuasa T, Yoshiki T, et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res. 2000;6(8):3166-71. (Pubitemid 30637743)
71. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106(5):710-5.
72. Gazzaniga P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res. 2001;7(3):577-83. (Pubitemid 32707981)
73. Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol. 2009;20(2):305-8.
74. Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011;107(10):1668-75.
75. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810-7.
76. Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a cell search analysis. Ann Oncol. 2012;23(9):2352-6.
77. Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011;78(4):863-7.
78. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008;100(19):1401-11.
79. Tilki D, Singer BB, Shariat SF, Behrend A, Fernando M, Irmak S, et al. CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol. 2010;57(4):648-54.
80. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294(16):2052-6. (Pubitemid 41539938)
81. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;116(1):100-4. (Pubitemid 40827761)
82. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res. 1997;57(4):773-7. (Pubitemid 27085665)
83. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol. 2000;163(1):348-56.
84. Zuiverloon TC, Tjin SS, Busstra M, Bangma CH, Boeve ER, Zwarthoff EC. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J Urol. 2011;186(2):707-12.
85. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005;11(21):7743-8. (Pubitemid 41611617)
86. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011;60(3):484-92.
87. Urquidi V, Rosser CJ, Goodison S. Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem. 2012;19(22):3653-63.
88. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer. 2001;94(1):67-72. (Pubitemid 32801754)
89. Roupret M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 2008;101(11):1448-53. (Pubitemid 351623989)
90. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5(11):e13821.
91. van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol. 2009;55(3):659-67.
92. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16(11):3011-8.
93. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002;8(2):464-70. (Pubitemid 34193966)
94. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004;10(22):7457-65. (Pubitemid 39557507)
95. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004;10(6):1887-93. (Pubitemid 38375544)
96. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010;58(1):96-104.
97. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006;98(14):996-1004. (Pubitemid 44288164)
98. Reinert T. Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol. 2012;2012:503271.
99. Phe V, Cussenot O, Roupret M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009;104(7):896-901.
100. Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 2012;188(6):2101-7.
101. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1483-91.
102. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011;6(9):1120-30.
103. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671-81.
104. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851-60.
105. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6(3):e18286.
106. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41(5):1871-8.
107. Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2012;15:1-5.
108. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180(5):1808-15.
109. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102(3):522-9.
110. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28(6):655-61.
111. Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 2012;107(1):123-8.
112. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2012 [Epub ahead of print].
113. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24(5):778-89. (Pubitemid 46622045)
114. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11(11):4044-55. (Pubitemid 40791568)
115. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007;13(12):3545-51. (Pubitemid 46955114)
116. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13(15 Pt 1):4407-14. (Pubitemid 47219707)
117. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005;11(21):7709-19. (Pubitemid 41611613)
118. Holyoake A, O'Sullivan P, Pollock R, Best T, Watanabe J, Kajita Y, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res. 2008;14(3):742-9. (Pubitemid 351231155)
119. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012;188(3):741-7.
120. Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke JM. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem. 2007;53(12):2070-7. (Pubitemid 350197289)
121. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol. 2010;183(2):493-8.
122. Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Muller M, et al. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 2007;245(1-2):121-6. (Pubitemid 44959342)
123. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol. 2008;134(6):659-65.
124. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 2009;18(2):444-53.
125. Mengual L, Burset M, Ribal MJ, Ars E, Marin-Aguilera M, Fernandez M, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010;16(9):2624-33.
126. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2149-58.
127. Sun Y, Todorovic S, Goodison S. Local-learning-based feature selection for high-dimensional data analysis. IEEE Trans Pattern Anal Mach Intell. 2010;32(9):1610-26.
128. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics. 2007;23(1):30-7. (Pubitemid 46017852)
129. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate. 2009;69(10):1119-27.
130. Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment choices based on OncotypeDx in the breast oncology care setting. J Cancer Epidemiol. 2012;2012:941495.
131. Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29(22):2959-64.
132. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, et al. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer. 2012;118(10):2641-50.
133. Kelly JD, Dudderidge TJ, Wollenschlaeger A, Okoturo O, Burling K, Tulloch F, et al. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22. PLoS One. 2012;7(7):e40305.
134. Margel D, Pesvner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol. 2011;59(1):113-9.
135. Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol. 1996;155(6):2105-12. (Pubitemid 26146716)
136. Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH, et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 2012;11(12):5611-29.
137. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15(3):1024-31.
138. Schwamborn K, Krieg RC, Grosse J, Reulen N, Weiskirchen R, Knuechel R, et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol. 2009;56(6):989-96.
139. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol. 1996;155(6):2113-9. (Pubitemid 26146717)
140. Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, et al. Stage-dependent increase of orosomucoid and zinc-alpha(2)-glycoprotein in urinary bladder cancer. Proteomics. 2005;5(16):4296-304. (Pubitemid 41626097)
141. Orenes-Piñero E, Corton M, Gonzalez-Peramato P, Algaba F, Casal I, Serrano A, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res. 2007;6(11):4440-8. (Pubitemid 350158519)
142. Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Oofusa K, et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol. 2005;48(5):865-71. (Pubitemid 41495397)
143. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001;158(4):1491-502. (Pubitemid 32281313)
144. Holterman DA, Diaz JI, Blackmore PF, Davis JW, Schellhammer PF, Corica A, et al. Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol. 2006;24(2):97-108. (Pubitemid 43340166)
145. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7(3):230-40. (Pubitemid 43286453)
146. Chen YT, Chen CL, Chen HW, Chung T, Wu CC, Chen CD, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res. 2010;9(11):5803-15.
147. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res. 2011;17(10):3349-59.
148. Feng S, Yang N, Pennathur S, Goodison S, Lubman DM. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem. 2009;81(10):3776-83.
149. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology. 2012;79(5):1185, e1-6.
150. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol. 2012;188(6):2377-83.
151. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One. 2012;7(5):e37797.
152. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One. 2012;7(10):e47469.
153. Hyndman ME, Mullins JK, Bivalacqua TJ. Metabolomics and bladder cancer. Urol Oncol. 2011;29(5):558-61.
154. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol. 2008;179(6):2422-6.
155. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res. 2010;9(6):2988-95.
156. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71(24):7376-86.
157. Cao M, Zhao L, Chen H, Xue W, Lin D. NMR-based metabolomic analysis of human bladder cancer. Anal Sci. 2012;28(5):451-6.